ID   HCC-3
AC   CVCL_0C57
AS   CVCL_0C55
SY   HCC.3; HCC3; AKH13
DR   cancercelllines; CVCL_0C57
DR   Cosmic; 1628384
DR   Cosmic; 2162535
DR   TOKU-E; 3990
DR   Wikidata; Q54749093
RX   PubMed=16809312;
RX   PubMed=18594539;
RX   PubMed=23887712;
RX   PubMed=31063779;
WW   https://lccl.zucmanlab.com/hcc/cellLines/HCC.3
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Unspecified (PubMed=31063779).
CC   Omics: Deep exome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Miscellaneous: Direct author submission of STR profile from Rohr-Udilova N.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 12
ST   D18S51: 14,17
ST   D21S11: 29
ST   D3S1358: 17,18
ST   D5S818: 13
ST   D7S820: 11
ST   D8S1179: 14,15
ST   FGA: 20
ST   Penta D: 9
ST   Penta E: 7,13
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C3098; Hepatitis C infection
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0C49 ! MF-3
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 05-10-23; Version: 10
//
RX   PubMed=16809312; DOI=10.1128/JVI.00020-06;
RA   Metzl C., Mischek D., Salmons B., Gunzburg W.H., Renner M.,
RA   Portsmouth D.;
RT   "Tissue- and tumor-specific targeting of murine leukemia virus-based
RT   replication-competent retroviral vectors.";
RL   J. Virol. 80:7070-7078(2006).
//
RX   PubMed=18594539; DOI=10.1038/sj.bjc.6604440;
RA   Sagmeister S., Eisenbauer M., Pirker C., Mohr T., Holzmann K.,
RA   Zwickl H., Bichler C., Kandioler D., Wrba F., Mikulits W., Gerner C.,
RA   Shehata M., Majdic O., Streubel B., Berger W., Micksche M.,
RA   Zatloukal K., Schulte-Hermann R., Grasl-Kraupp B.;
RT   "New cellular tools reveal complex epithelial-mesenchymal interactions
RT   in hepatocarcinogenesis.";
RL   Br. J. Cancer 99:151-159(2008).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//